Media stories about ResMed (NYSE:RMD) have trended somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies negative and positive media coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. ResMed earned a coverage optimism score of 0.20 on Accern’s scale. Accern also assigned headlines about the medical equipment provider an impact score of 45.6909246832399 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
These are some of the news headlines that may have impacted Accern Sentiment’s scoring:
- Trending Shares: ResMed Inc. (RMD) stock price settles at $98.33 with movement of 0.15% – Nasdaq Express (nasdaqexpress.com)
- Zacks: Analysts Expect ResMed Inc. (RMD) Will Post Quarterly Sales of $562.33 Million (americanbankingnews.com)
- These Two Stocks in Motion: ResMed Inc. (NYSE:RMD), Apricus Biosciences, Inc. (NASDAQ:APRI) – The Oracle Examiner (oracleexaminer.com)
- Eye-Catching Shares – ResMed Inc (NYSE: RMD) – Alpha Beta Stock (alphabetastock.com)
- Technical Review on ResMed Inc. (RMD) – Wall Street Morning (wallstreetmorning.com)
RMD has been the subject of several analyst reports. BMO Capital Markets raised their price target on shares of ResMed to $82.00 and gave the company a “market perform” rating in a research note on Tuesday, December 12th. Zacks Investment Research downgraded shares of ResMed from a “hold” rating to a “sell” rating in a research note on Tuesday, December 26th. Needham & Company LLC raised shares of ResMed from an “underperform” rating to a “hold” rating in a research note on Tuesday, January 23rd. Macquarie downgraded shares of ResMed from a “neutral” rating to a “sell” rating in a research note on Tuesday, January 23rd. Finally, Northland Securities raised shares of ResMed from an “under perform” rating to a “market perform” rating in a research note on Tuesday, January 23rd. Three research analysts have rated the stock with a sell rating, six have assigned a hold rating and five have issued a buy rating to the stock. ResMed presently has a consensus rating of “Hold” and an average price target of $75.17.
ResMed (NYSE:RMD) last announced its earnings results on Monday, January 22nd. The medical equipment provider reported $1.00 earnings per share for the quarter, topping analysts’ consensus estimates of $0.78 by $0.22. ResMed had a net margin of 12.98% and a return on equity of 22.75%. The business had revenue of $601.27 million during the quarter, compared to the consensus estimate of $583.77 million. During the same quarter last year, the firm earned $0.73 earnings per share. ResMed’s quarterly revenue was up 13.4% on a year-over-year basis. equities research analysts anticipate that ResMed will post 3.34 EPS for the current year.
The company also recently announced a quarterly dividend, which was paid on Thursday, March 15th. Investors of record on Thursday, February 8th were paid a dividend of $0.35 per share. This represents a $1.40 dividend on an annualized basis and a yield of 1.45%. The ex-dividend date was Wednesday, February 7th. ResMed’s dividend payout ratio is presently 70.00%.
In related news, insider James Hollingshead sold 600 shares of ResMed stock in a transaction on Tuesday, January 2nd. The shares were sold at an average price of $84.96, for a total transaction of $50,976.00. Following the completion of the transaction, the insider now owns 62,602 shares of the company’s stock, valued at $5,318,665.92. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider Richard Mchale sold 2,000 shares of ResMed stock in a transaction on Thursday, February 1st. The stock was sold at an average price of $100.12, for a total transaction of $200,240.00. Following the transaction, the insider now directly owns 62,002 shares of the company’s stock, valued at approximately $6,207,640.24. The disclosure for this sale can be found here. Insiders have sold 46,139 shares of company stock valued at $4,595,966 in the last three months. 1.77% of the stock is owned by insiders.
WARNING: “Somewhat Positive News Coverage Somewhat Unlikely to Impact ResMed (RMD) Stock Price” was first posted by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this piece on another publication, it was copied illegally and reposted in violation of U.S. & international copyright & trademark law. The original version of this piece can be viewed at https://stocknewstimes.com/2018/03/22/somewhat-positive-news-coverage-somewhat-unlikely-to-impact-resmed-rmd-stock-price.html.
ResMed Inc is a holding company. The Company is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease (COPD), neuromuscular disease and other diseases.
Receive News & Ratings for ResMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed and related companies with MarketBeat.com's FREE daily email newsletter.